PATENT CLAIM ANALYSIS

Application Number: 15892989
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["548", "139000"]

Abstract:
The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods.

Claim (Index 17):
The method of  claim 13 , wherein the methazolamide and metformin are administered orally, either simultaneously or separately.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 88.0
- Lexical Diversity: 1.54545
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12524146', '13081548', '13467707', '13321103', '13467757']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5396982057306204
- 35 USC 102 Novelty (BERT): 0.5114679182144495
- Combined Prediction Score: 0.5368751769790033
- Mean Citation Score: 229.265532
- Max Citation Score: 233.1197
- Similarity Product: 153.67613579627275

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test